|
Wednesday, January 27, 2016 10:29 PM
|
CCSVI in Multiple Sclerosis
New Research: Tysabri usage changes status in patients from JC- to JC+ This "seroconversion" happened in over 10% of people on Tysabri. Please read and share this study. Bottom line---using Tysabri has a ten time higher risk of seroconversion to JC+ and potential PML than thought previously. How this drug received approval without this understanding is beyond comprehension. Joan http://nn.neurology.org/content/3/1/e195.full![Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values]() I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.
|